The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): Membrane proteins engaged in matrix turnover during tissue remodeling

Biological Chemistry

Volumn 385, Issue 2, 2004, Pages 103-136

  Behrendt, Neils ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Cascade; Collagen; Endocytosis; Plasminoigen; Proteolysis

Indexed keywords

ADAPTOR PROTEIN; CARBOHYDRATE BINDING PROTEIN; CELL SURFACE PROTEIN; CELL SURFACE RECEPTOR; COLLAGEN; CYSTEINE; ENZYME PRECURSOR; GLYCOPROTEIN; INTEGRIN; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL; PLASMINOGEN; PROTEIN ENDO180; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; UROKINASE RECEPTOR ASSOCIATED PROTEIN;

BINDING SITE; CELL FUNCTION; CELL INTERACTION; CELL SURFACE; CELL TRANSPORT; CELL TYPE; DEGRADATION KINETICS; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENETIC MANIPULATION; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; STOICHIOMETRY; TISSUE DISTRIBUTION;

ANIMALS; COLLAGEN; EXTRACELLULAR MATRIX; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, MOLECULAR; NEOPLASMS; PLASMINOGEN; RECEPTORS, CELL SURFACE; RECEPTORS, MITOGEN; SIGNAL TRANSDUCTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 1842787815     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2004.031     Document Type: Review

References (264)

1. Aguirre Ghiso, J.A., Kovalski, K., and Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104.
2. Aimes, R.T., Regazzoni, K., and Quigley, J.P. (2003). Human/chicken urokinase chimeras demonstrate sequences outside the serine protease domain that dictate autoactivation. Thromb. Haemost. 89, 382-392.
3. Ancian, P., Lambeau, G., and Lazdunski, M. (1995). Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2. Biochemistry 34, 13146-13151.
4. Andolfo, A., English, W.R., Resnati, M., Murphy, G., Blasi, F., and Sidenius, N. (2002). Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb. Haemost. 88, 298-306.
5. Andreasen, P.A., Georg, B., Lund, L.R., Riccio, A., and Stacey, S.N. (1990). Plasminogen activator inhibitors: Hormonally regulated serpins. Mol. Cell Endocrinol. 68, 1-19.
6. Andreasen, P.A., Kjøller, L., Christensen, L., and Duffy, M.J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer 72, 1-22.
7. Andreasen, P.A., Egelund, R., and Petersen, H.H. (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 57, 25-40.
8. Appella, E., Robinson, E.A., Ullrich, S.J., Stoppelli, M.P., Corti, A., Cassani, G., and Blasi, F. (1987). The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem. 262, 4437-4440.
9. Arora, P.D., Manolson, M.F., Downey, G.P., Sodek, J., and McCulloch, C.A. (2000). A novel model system for characterization of phagosomal maturation, acidification, and intracellular collagen degradation in fibroblasts. J. Biol. Chem 275, 35432-35441.
10. Bajpai, A. and Baker, J.B. (1985). Cryptic urokinase binding sites on human foreskin fibroblasts. Biochem. Biophys. Res. Commun. 133, 475-482.
11. Balcerzak, D., Querengesser, L., Dixon, W.T., and Baracos, V.E. (2001). Coordinate expression of matrix-degrading proteinases and their activators and inhibitors in bovine skeletal muscle. J. Anim Sci. 79, 94-107.
12. Banyai, L., Tordai, H., and Patthy, L. (1994). The gelatin-binding site of human 72 kDa type IV collagenase (gelatinase A). Biochem. J. 298, 403-407.
13. Bdeir, K., Kuo, A., Mazar, A., Sachais, B.S., Xiao, W., Gawlak, S., Harris, S., Higazi, A.A., and Cines, D.B. (2000). A region in domain II of the urokinase receptor required for urokinase binding. J. Biol. Chem 275, 28532-28538.
14. Behrendt, N., Rønne, E., Ploug, M., Petri, T, Løber, D., Nielsen, L.S., Schleuning, W.D., Blasi, F., Appella, E., and Danø, K. (1990). The human receptor for urokinase plasminogen activator. NH2- terminal amino acid sequence and glycosylation variants. J. Biol. Chem. 265, 6453-6460.
15. Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Danø, K. (1991). The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem. 266, 7842-7847.
16. Behrendt, N., Rønne, E., and Danø, K. (1993a). Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J. Biol. Chem. 268, 5985-5989.
17. Behrendt, N., Rønne, E., and Danø, K. (1993b). A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking. FEBS Lett. 336, 394-396.
18. Behrendt, N. and Danø, K. (1996). Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Lett. 393, 31-36.
19. Behrendt, N., Rønne, E., and Danø, K. (1996). Domain interplay in the urokinase receptor-Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J. Biol. Chem. 271, 22885-22894.
20. Behrendt, N. and Danø, K. (1997). Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi). FEES Lett. 402, 293-294.
21. Behrendt, N. and Stephens, R.W. (1998). The urokinase receptor. Fibrinolysis Proteolysis 12, 191-204.
22. Behrendt, N., Jensen, O.N., Engelholm, L.H., Mørtz, E., Mann, M., and Danø, K. (2000). A urokinase receptor-associated protein with specific collagen binding properties. J. Biol. Chem. 275, 1993-2002.
23. Behrendt, N., List, K., Andreasen, P.A., and Danø, K. (2003). The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: Rescue of activity through reciprocal pro-enzyme activation. Biochem. J. 371, 277-287.
24. Bianchi, E., Cohen, R.L., Thor, A.T., Todd, R.F., III, Mizukami, I.F., Lawrence, D.A., Ljung, B.M., Shuman, M.A., and Smith, H.S. (1994). The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 54, 861-866.
25. Blasi, F. and Carmeliet, P. (2002). uPAR: A versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943.
26. Bohuslav, J., Horejsi, V., Hansmann, C., Stockl, J., Weidle, U.H., Majdic, O., Bartke, I., Knapp, W., and Stockinger, H. (1995). Urokinase plasminogen activator receptor, β 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181, 1381-1390.
27. Briknarova, K., Gehrmann, M., Banyai, L., Tordai, H., Patthy, L., and Llinas, M. (2001). Gelatin-binding region of human matrix metalloproteinase-2: Solution structure, dynamics, and function of the COL-23 two-domain construct. J. Biol. Chem. 276, 27613-27621.
28. Brownstein, C., Falcone, D.J., Jacovina, A., and Hajjar, K.A. (2001). A mediator of cell surface-specific plasmin generation. Ann. N. Y. Acad. Sci. 947, 143-155.
29. Brunner, G., Simon, M.M., and Kramer, M.D. (1990). Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1. FEBS Lett. 260, 141-144.
30. Bugge, T.H., Flick, M.J., Daugherty, C.C., and Degen, J.L. (1995a). Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9, 794-807.
31. Bugge, T.H., Suh, T.T., Flick, M.J., Daugherty, C.C., Rømer, J., Solberg, H., Ellis, V., Danø, K., and Degen, J.L. (1995b). The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270, 16886-16894.
32. Bugge, T.H., Flick, M.J., Danton, M.J., Daugherty, C.C., Rømer, J., Danø, K., Carmeliet, P., Collen, D., and Degen, J.L. (1996). Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 93, 5899-5904.
33. Bugge, TH., Lund, L.R., Kombrinck, K.K., Nielsen, B.S., Holmbäck, K., Drew, A.F., Flick, M.J., Witte, D.P., Danø, K., and Degen, J.L. (1998). Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16, 3097-3104.
34. Busso, N., Masur, S.K., Lazega, D., Waxman, S., and Ossowski, L. (1994). Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126, 259-270.
35. Bürgle, M., Koppitz, M., Riemer, C., Kessler, H., König, B., Weidle, U.H., Kellermann, J., Lottspeich, F., Graeff, H., Schmitt, M. et al. (11997). Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol. Chem. 378, 231-237.
36. Børglum, A.D., Byskov, A., Ragno, P., Roldan, A.L., Tripputi, P., Cassani, G., Danø, K., Blasi, F., Bolund, L., and Kruse, T.A. (1992). Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. Am. J. Hum. Genet. 50, 492-497.
37. Carmeliet, R, Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J.J., Collen, D., and Mulligan, R.C. (1994). Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419-424.
38. Carmeliet, P. and Collen, D. (1995). Gene targeting and gene transfer studies of the plasminogen/plasmin system: Implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J. 9, 934-938.
39. Carmeliet, P., Moons, L., Herbert, J.M., Crawley, J., Lupu, F., Lijnen, R., and Collen, D. (1997). Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ. Res. 81, 829-839.
40. Carmeliet, P., Moons, L., Dewerchin, M., Rosenberg, S., Herbert, J.M., Lupu, F., and Collen, D. (1998). Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J. Cell Biol. 140, 233-245.
41. Carriero, M.V., Franco, P., Gargiulo, L., Vocca, I., Cito, L., Fontana, L., Iaccarino, C., Del Pozzo, G., Guardiola, J., and Stoppelli, M.P. (2002). Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions. Biol. Chem. 383, 107-113.
42. Casey, J.R., Petranka, J.G., Kottra, J., Fleenor, D.E., and Rosse, W.F. (1994). The structure of the urokinase-type plasminogen activator receptor gene. Blood 84, 1151-1156.
43. Chapman, H.A. and Wei, Y. (2001). Protease crosstalk with integrins: The urokinase receptor paradigm. Thromb. Haemost. 86, 124-129.
44. Chavakis, T., Kanse, S.M., Lupu, F., Hammes, H.P., Muller-Esterl, W., Pixley, R.A., Colman, R.W., and Preissner, K.T. (2000). Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 96, 514-522.
45. Coleman, P.L., Patel, P.D., Cwikel, B.J., Rafferty, U.M., Sznycer-Laszuk, R., and Gelehrter, T.D. (1986). Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J. Biol. Chem. 261, 4352-4357.
46. Colman, R.W., Pixley, R.A., Najamunnisa, S., Yan, W., Wang, J., Mazar, A., and McCrae, K.R. (1997). Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J. Clin. Invest. 100, 1481-1487.
47. Conese, M., Olson, D., and Blasi, F. (1994). Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor. J. Biol. Chem. 269, 17886-17892.
48. Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490.
49. Creemers, E., Cleutjens, J., Smits, J., Heymans, S., Moons, L., Collen, D., Daemen, M., and Carmeliet, P. (2000). Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am. J. Pathol. 156, 1865-1873.
50. Crowley, C.W., Cohen, R.L., Lucas, B.K., Liu, G., Shuman, M.A., and Levinson, A.D. (1993). Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 90, 5021-5025.
51. Cubellis, M.V., Nolli, M.L., Cassani, G., and Blasi, F. (1986). Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J. Biol. Chem. 261, 15819-15822.
52. Cubellis, M.V., Wun, T.C., and Blasi, F. (1990). Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 9, 1079-1085.
53. Cunningham, O., Andolfo, A., Santovito, M.L., Iuzzolino, L., Blasi, F., and Sidenius, N. (2003). Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J. 22, 5994-6003.
54. Czekay, R.P., Kuemmel, T.A., Orlando, R.A., and Farquhar, M.G. (2001). Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 12, 1467-1479.
55. Danø, K., Andreasen, P.A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L.S., and Skriver, L. (1985). Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44, 139-266.
56. Danø, K., Rømer, J., Nielsen, B.S., Bjørn, S., Pyke, C., Rygaard, J., and Lund, L.R. (1999). Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107, 120-127.
57. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S., and Loskutoff, D.J. (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571.
58. Dewerchin, M., Nuffelen, A.V., Wallays, G., Bouche, A., Moons, L., Carmeliet, P., Mulligan, R.C., and Collen, D. (1996). Generation and characterization of urokinase receptor-deficient mice. J. Clin. Invest. 97, 870-878.
59. Drag, B. and Petersen, L.C. (1994). Activation of pro-urokinase by cathepsin G in the presence of glucosaminoglycans. Fibrinolysis 8, 192-199.
60. Dumler, I., Kopmann, A., Wagner, K., Mayboroda, O.A., Jerke, U., Dietz, R., Haller, H., and Gulba, D.C. (1999). Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells. J. Biol. Chem. 274, 24059-24065.
61. Dvorak, H.F., Orenstein, N.S., Rypysc, J., Colvin, R.B., and Dvorak, A.M. (1978). Plasminogen activator of guinea pig basophilic leukocytes: Probable localization to the plasma membrane. J. Immunol. 120, 766-773.
62. East, L. and Isacke, C.M. (2002). The mannose receptor family. Biochim. Biophys. Acta 1572, 364-386.
63. East, L., Rushton, S., Taylor, M.E., and Isacke, C.M. (2002). Characterization of sugar binding by the mannose receptor family member, Endo180. J. Biol. Chem. 277, 50469-50475.
64. East, L., McCarthy, A., Wienke, D., Sturge, J., Ashworth, A., and Isacke, C.M. (2003). A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake. EMBO Rep. 4, 710-716.
65. Ellis, V., Scully, M.F., and Kakkar, V.V. (1989). Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem. 264, 2185-2188.
66. Ellis, V., Wun, T.C., Behrendt, N., Ronne, E., and Danø, K. (1990). Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J. Biol. Chem. 265, 9904-9908.
67. Ellis, V., Behrendt, N., and Danø, K. (1991). Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J. Biol. Chem. 266, 12752-12758.
68. Ellis, V. and Danø, K. (1993). Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. J. Biol. Chem. 268, 4806-4813.
69. Ellis, V. (1996). Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. J. Biol. Chem. 271, 14779-14784.
70. Engelholm, L.H. and Behrendt, N. (2001). Differential binding of urokinase and peptide antagonists to the urokinase receptor: Evidence from characterization of the receptor in four primate species. Biol. Chem. 382, 435-442.
71. Engelholm, L.H., Nielsen, B.S., Danø, K., and Behrendt, N. (2001a). The urokinase receptor associated protein (uPARAP/endo180): A novel internalization receptor connected to the plasminogen activation system. Trends Cardiovasc. Med. 11, 7-13.
72. Engelholm, L.H., Nielsen, B.S., Netzel-Arnett, S., Solberg, H., Chen, X.D., Lopez Garcia, J.M., Lopez-Otin, C., Young, M.F., Birkedal-Hansen, H., Danø, K. et al. (2001b). The urokinase plasminogen activator receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis. Lab. Invest. 81, 1403-1414.
73. Engelholm, L.H., List, K., Netzel-Arnett, S., Cukierman, E., Mitola, D.J., Aaronson, H., Kjøller, L., Larsen, J.K., Yamada, K.M., Strickland, D.K. et al. (2003). uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J. Cell Biol. 160, 1009-1015.
74. Estreicher, A., Wohlwend, A., Belin, D., Schleuning, W.D., and Vassalli, J.D. (1989). Characterization of the cellular binding site for the urokinase-type plasminogen activator. J. Biol. Chem. 264, 1180-1189.
75. Estreicher, A., Muhlhauser, J., Carpentier, J.L., Orci, L., and Vassalli, J.D. (1990). The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111, 783-792.
76. Everts, V., van der, Z. E., Creemers, L., and Beertsen, W. (1996). Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem. J. 28, 229-245.
77. Fazioli, F., Resnati, M., Sidenius, N., Higashimoto, Y., Appella, E., and Blasi, F. (1997). A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16, 7279-7286.
78. Feinberg, H., Park-Snyder, S., Kolatkar, A.R., Heise, C.T., Taylor, M.E., and Weis, W.I. (2000). Structure of a C-type carbohydrate recognition domain from the macrophage mannose receptor. J. Biol. Chem. 275, 21539-21548.
79. Fiete, D.J., Beranek, M.C., and Baenziger, J.U. (1998). A cysteine-rich domain of the 'mannose' receptor mediates GalNAc-4-SO4 binding. Proc. Natl. Acad. Sci. USA 95, 2089-2093.
80. Fleming, T.J., O'hUigin, C., and Malek, T.R. (1993). Characterization of two novel Ly-6 genes. Protein sequence and potential structural similarity to alpha-bungarotoxin and other neurotoxins. J. Immunol. 150, 5379-5390.
81. Fletcher, C.M., Harrison, R.A., Lachmann, P.J., and Neuhaus, D. (1994). Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure 2, 185-199.
82. Fowler, B., Mackman, N., Parmer, R.J., and Miles, L.A. (1998). Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR. Thromb. Haemost. 80, 148-154.
83. Franco, P., Iaccarino, C., Chiaradonna, F, Brandazza, A., Iavarone, C., Mastronicola, M.R., Nolli, M.L., and Stoppelli, M.P. (1997). Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J. Cell Biol. 137, 779-791.
84. Frenette, G., Tremblay, R.R., Lazure, C., and Dube, J.Y. (1997). Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 71, 897-899.
85. Fujiyama, C., Jones, A., Fuggle, S., Bicknell, R., Cranston, D., and Harris, A.L. (2001). Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br. J. Cancer 84, 558-564.
86. Geiger, M., Priglinger, U., Griffin, J.H., and Binder, B.R. (1991). Urinary protein C inhibitor. Glycosaminoclycans synthesized by the epithelial kidney cell line TCL-598 enhance its interaction with urokinase. J. Biol. Chem. 266, 11851-11857.
87. Gonzalez-Gronow, M., Gawdi, G., and Pizzo, S.V. (2002). Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. Blood 99, 4562-4567.
88. Goodson, R.J., Doyle, M.V., Kaufman, S.E., and Rosenberg, S. (1994). High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA 91, 7129-7133.
89. Goretzki, L., Schmitt, M., Mann, K., Calvete, J., Chucholowski, N., Kramer, M., Gunzler, W.A., Janicke, F., and Graeff, H. (1992). Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett. 297, 112-118.
90. Gyetko, M.R., Todd, R.F., III, Wilkinson, C.C., and Sitrin, R.G. (1994). The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. 93, 1380-1387.
91. Gyetko, M.R., Sud, S., Kendall, T., Fuller, J.A., Newstead, M.W., and Standiford, T.J. (2000). Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J. Immunol. 165, 1513-1519.
92. Gårdsvoll, H., Danø, K., and Ploug, M. (1999). Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J. Biol. Chem. 274, 37995-38003.
93. Heegaard, C.W., Simonsen, A.C., Oka, K., Kjøller, L., Christensen, A., Madsen, B., Ellgaard, L., Chan, L., and Andreasen, P.A. (1995). Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J. Biol. Chem. 270, 20855-20861.
94. Herz, J., Clouthier, D.E., and Hammer, R.E. (1992). LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71, 411-421.
95. Higazi, A., Cohen, R.L., Henkin, J., Kniss, D., Schwartz, B.S., and Cines, D.B. (1995). Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J. Biol. Chem. 270, 17375-17380.
96. Higazi, A.A., Mazar, A., Wang, J., Reilly, R., Henkin, J., Kniss, D., and Cines, D. (1996). Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 87, 3545-3549.
97. Higazi, A.A. (1997). Commentary on: 'Effect of purified soluble urokinase receptor on the plasminogen prourokinase activation system' by N. Behrendt and K. Dano, FEBS Letters, 393 (1996) 31-36. FEBS Lett. 402, 291-292.
98. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S.A., Mankani, M., Robey, P.G., Poole, A.R., Pidoux, I., Ward, J.M., and Birkedal-Hansen, H. (1999). MT1 -MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92
99. Howard, M.J. and Isacke, C.M. (2002). The C-type lectin receptor Endo180 displays internalization and recycling properties distinct from other members of the mannose receptor family. J. Biol. Chem. 277, 32320-32331.
100. Howard, M.J., Chambers, M.G., Mason, R.M., and Isacke, C.M. (2003). Distribution of Endo180 receptor and ligand in developing articular cartilage. Osteoarthr. Cartil. 12, 74-82.
101. Høyer-Hansen, G., Rønne, E., Solberg, H., Behrendt, N., Ploug, M., Lund, L.R., Ellis, V., and Danø, K. (1992). Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267, 18224-18229.
102. Høyer-Hansen, G., Ploug, M., Behrendt, N., Rønne, E., and Danø, K. (1997a). Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur. J. Biochem. 243, 21-26.
103. Høyer-Hansen, G., Behrendt, N., Ploug, M., Danø, K., and Preissner, K.T. (1997b). The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction. FEBS Lett. 420, 79-85.
104. Høyer-Hansen, G., Pessara, U., Holm, A., Pass, J., Weidle, U., Danø, K., and Behrendt, N. (2001). Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem. J. 358, 673-679.
105. Ichinose, A., Fujikawa, K., and Suyama, T. (1986). The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 261, 3486-3489.
106. Isacke, C.M., van der Geer, P., Hunter, T., and Trowbridge, I.S. (1990). p180, a novel recycling transmembrane glycoprotein with restricted cell type expression. Mol. Cell. Biol. 10, 2606-2618.
107. Ishikawa, K., Nagase, T., Suyama, M., Miyajima, N., Tanaka, A., Kotani, H., Nomura, N., and Ohara, O. (1998). Prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res. 5, 169-176.
108. Jaken, S. and Black, P.H. (1979). Differences in intracellular distribution of plasminogen activator in growing, confluent, and transformed 3T3 cells. Proc. Natl. Acad. Sci. USA 76, 246-250.
109. Jo, M., Thomas, K.S., O'Donnell, D.M., and Gonias, S.L. (2003). Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J. Biol. Chem. 278, 1642-1646.
110. Johnsen, M., Lund, L.R., Rømer, J., Almholt, K., and Danø, K. (1998). Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol. 10, 667-671.
111. Kanse, S.M., Kost, C., Wilhelm, O.G., Andreasen, P.A., and Preissner, K.T. (1996). The urokinase receptor is a major vitro-nectin-binding protein on endothelial cells. Exp. Cell Res. 224, 344-353.
112. Ke, S.H., Coombs, G.S., Tachias, K., Corey, D.R., and Madison, E.L. (1997). Optimal subsite occupancy and design of a selective inhibitor of urokinase. J. Biol. Chem. 272, 20456-20462.
113. Kieffer, B., Driscoll, P.C., Campbell, I.D., Willis, A.C., van der Merwe, P.A., and Davis, S.J. (1994). Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins. Biochemistry 33, 4471-4482.
114. Kindzelskii, A.L., Laska, Z.O., Todd, R.F., III, and Petty, H.R. (1996). Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2′ CD11b/CD18) during neutrophil polarization. J. Immunol. 156, 297-309.
115. Kjøller, L. and Hall, A. (2001). Rac mediates cytoskeletal rear-rangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152, 1145-1157.
116. Kjøller, L. (2002). The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol. Chem. 383, 5-19.
117. Kjøller, L., Engelholm, L.H., Høyer-Hansen, M., Danø , K., Bugge, T.H., and Behrendt, N. (2004). uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Exp. Cell Res. 293, 106-116.
118. Kobayashi, H., Schmitt, M., Goretzki, L., Chucholowski, N., Calvete, J., Kramer, M., Günzler, W.A., Jänicke, F., and Graeff, H. (1991). Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J. Biol. Chem. 266, 5147-5152.
119. Kobayashi, H., Gotoh, J., Fujie, M., Shinohara, H., Moniwa, N., and Terao, T. (1994). Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer 57, 727-733.
120. Koshelnick, Y., Ehart, M., Hufnagl, P., Heinrich, P.C., and Binder, B.R. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272, 28563-28567.
121. Kounnas, M.Z., Henkin, J., Argraves, W.S., and Strickland, D.K. (1993). Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of prourokinase. J. Biol. Chem. 268, 21862-21867.
122. Kristensen, P., Eriksen, J., Blasi, F., and Danø, K. (1991). Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J. Cell Biol. 115, 1763-1771.
123. Kruithof, E.K. (1988). Plasminogen activator inhibitors-a review. Enzyme 40, 113-121.
124. Lee, W., Sodek, J., and McCulloch, C.A. (1996). Role of integrins in regulation of collagen phagocytosis by human fibroblasts. J. Cell. Physiol. 168, 695-704.
125. Lee, S.L., Dickson, R.B., and Lin, C.Y. (2000). Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275, 36720-36725.
126. Li, Y., Lawrence, D.A., and Zhang, L. (2003). Sequences within domain II of the urokinase receptor critical for differential ligand recognition. J. Biol. Chem 278, 29925-29932.
127. Lijnen, H.R. (2001). Elements of the fibrinolytic system. Ann. NY Acad. Sci. 936, 226-236.
128. List, K., Høyer-Hansen, G., Ronne, E., Danø, K., and Behrendt, N. (1999). Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: A study based on biosensor technology. J. Immunol. Methods 222, 125-133.
129. List, K., Jensen, O.N., Bugge, T.H., Lund, L.R., Ploug, M., Danø, K., and Behrendt, N. (2000). Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry 39, 508-515.
130. Liu, Y., Chirino, A.J., Misulovin, Z., Leteux, C., Feizi, T., Nussenzweig, M.C., and Bjorkman, P.J. (2000). Crystal structure of the cysteine-rich domain of mannose receptor complexed with a sulfated carbohydrate ligand. J. Exp. Med. 191, 1105-1116.
131. Liu, S., Bugge, T.H., and Leppla, S.H. (2001). Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem. 276, 17976-17984.
132. Liu, S., Aaronson, H., Mitola, D.J., Leppla, S.H., and Bugge, T.H. (2003). Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc. Natl. Acad. Sci. USA 100, 657-662.
133. Longstaff, C., Merton, R.E., Fabregas, P., and Felez, J. (1999). Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87). Blood 93, 3839-3846.
134. Lopez-Alemany, R., Longstaff, C., Hawley, S., Mirshahi, M., Fabregas, P., Jardi, M., Merton, E., Miles, L.A., and Felez, J. (2003). Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against α-enolase. Am. J. Hematol. 72, 234-242.
135. Lund, L.R., Rømer, J., Bugge, T.H., Nielsen, B.S., Frandsen, T.L., Degen, J.L., Stephens, R.W., and Danø, K. (1999). Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 18, 4645-4656.
136. Lund, L.R., Bjørn, S.F., Sternlicht, M.D., Nielsen, B.S., Solberg, H., Usher, P.A., Østerby, R., Christensen, I.J., Stephens, R.W., Bugge, T.H. et al. (2000). Lactational competence and involution of the mouse mammary gland require plasminogen. Development 127, 4481-4492.
137. Luther, T., Magdolen, V., Albrecht, S., Kasper, M., Riemer, C., Kessler, H., Graeff, H., Muller, M., and Schmitt, M. (1997). Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. Pathol. 150, 1231-1244.
138. Luther, T., Kotzsch, M., Meye, A., Langerholc, T., Fussel, S., Olbricht, N., Albrecht, S., Ockert, D., Muehlenweg, B., Friedrich, K. et al. (2003). Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb. Haemost. 89, 705-717.
139. Ma, Z., Webb, D.J., Jo, M., and Gonias, S.L. (2001). Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J. Cell Sci. 114, 3387-3396.
140. Magdolen, V., Bürgle, M., de Prada, N.A., Schmiedeberg, N., Riemer, C., Schroeck, F., Kellermann, J., Degitz, K., Wilhelm, O.G., Schmitt, M., and Kessler, H. (2001). Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol. Chem. 382, 1197-1205.
141. Manchanda, N. and Schwartz, B.S. (1991). Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. J. Biol. Chem. 266, 14580-14584.
142. Manchanda, N. and Schwartz, B.S. (1995). Interaction of single-chain urokinase and plasminogen activator inhibitor type 1. J. Biol. Chem. 270, 20032-20035.
143. Martinez-Pomares, L., Crocker, P.R., Da Silva, R., Holmes, N., Colominas, C., Rudd, P., Dwek, R., and Gordon, S. (1999). Cell-specific glycoforms of sialoadhesin and CD45 are counter-receptors for the cysteine-rich domain of the mannose receptor. J. Biol. Chem. 274, 35211-35218.
144. 2 integrins in vivo. J. Exp. Med. 188, 1029-1037.
145. McKerrow, J.H., Bhargava, V., Hansell, E., Huling, S., Kuwahara, T., Matley, M., Coussens, L., and Warren, R. (2000). A functional proteomics screen of proteases in colorectal carcinoma. Mol. Med. 6, 450-460.
146. Min, H.Y., Semnani, R., Mizukami, I.F., Watt, K., Todd, R.F., III, and Liu, D.Y. (1992). cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J. Immunol. 148, 3636-3642.
147. Min, H.Y., Doyle, L.V., Vitt, C.R., Zandonella, C.L., Stratton-Thomas, J.R., Shuman, M.A., and Rosenberg, S. (1996). Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56, 2428-2433.
148. Mingers, A.M., Philapitsch, A., Zeitler, P., Schuster, V., Schwarz, H.P., and Kreth, H.W. (1999). Human homozygous type I plasminogen deficiency and ligneous conjunctivitis. APMIS 107, 62-72.
149. Mizukami, I.F., Vinjamuri, S.D., Trochelman, R.D., and Todd, R.F., III (1990). A structural characterization of the Mo3 activation antigen expressed on the plasma membrane of human mononuclear phagocytes. J. Immunol. 144, 1841-1848.
150. Moestrup, S.K., Nielsen, S., Andreasen, P., Jørgensen, K.E., Nykjær, A., Røigaard, H., Gliemann, J., and Christensen, E.I. (1993). Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J. Biol. Chem. 268, 16564-16570.
151. Montuori, N., Carriero, M.V., Salzano, S., Rossi, G., and Ragno, P. (2002). The cleavage of the urokinase receptor regulates its multiple functions. J. Biol. Chem. 277, 46932-46939.
152. Murphy, G. and Gavrilovic, J. (1999). Proteolysis and cell migration: Creating a path? Curr. Opin. Cell Biol. 11, 614-621.
153. Mustjoki, S., Alitalo, R., Stephens, R.W., and Vaheri, A. (1999). Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: Relationship to classification and response to therapy. Thromb. Haemost. 81, 705-710.
154. Møller, L.B., Ploug, M., and Blasi, F. (1992). Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator. Eur. J. Biochem. 208, 493-500.
155. Møller, L.B., Pöllänen, J., Rønne, E., Pedersen, N., and Blasi, F. (1993). N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. J. Biol. Chem. 268, 11152-11159.
156. Nabeshima, K., Inoue, T., Shimao, Y., and Sameshima, T. (2002). Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol. Int. 52, 255-264.
157. Napper, C.E., Dyson, M.H., and Taylor, M.E. (2001). An extended conformation of the macrophage mannose receptor. J. Biol. Chem. 276, 14759-14766.
158. Nguyen, D.H., Hussaini, I.M., and Gonias, S.L. (1998). Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273, 8502-8507.
159. Nielsen, L.S., Kellerman, G.M., Behrendt, N., Picone, R., Danø, K., and Blasi, F. (1988). A 55 000-60 000 M, receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J. Biol. Chem. 263, 2358-2363.
160. Nykjær, A., Petersen, C.M., Møller, B., Jensen, PH., Moestrup, S.K., Holtet, T.L., Etzerodt, M., Thøgersen, H.C., Munch, M., Andreasen, P.A., and Gliemann, J. (1992). Purified α2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that the α2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J. Biol. Chem. 267, 14543-14546.
161. Nykjær, A., Møller, B., Todd, R.F., III, Christensen, T., Andreasen, P.A., Gliemann, J., and Petersen, C.M. (1994). Urokinase receptor. An activation antigen in human T lymphocytes. J. Immunol. 152, 505-516.
162. Nykjær, A., Conese, M., Christensen, E.I., Olson, D., Cremona, O., Gliemann, J., and Blasi, F. (1997). Recycling of the urokinase receptor upon internalization of the uPA:sErpin complexes. EMBO J. 16, 2610-2620.
163. Nykjær, A., Christensen, E.I., Vorum, H., Hager, H., Petersen, C.M., Røigaard, H., Min, H.Y., Vilhardt, F., Mø ller, L.B., Kornfeld, S., and Gliemann, J. (1998). Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell Biol. 141, 815-828.
164. Oda, M., Shiraishi, A., and Hasegawa, M. (1998). Analysis of the ternary complex formation of human urokinase with the separated two domains of its receptor. Eur. J. Biochem. 256, 411-418.
165. Ortega, N., Behonick, D., Stickens, D., and Werb, Z. (2003). How proteases regulate bone morphogenesis. Ann. NY Acad. Sci. 995, 109-116.
166. Palfree, R.G. (1991). The urokinase-type plasminogen activator receptor is a member of the Ly-6 superfamily. Immunol. Today 12, 170.
167. Pedersen, T.L., Plesner, T., Horn, T., Hoyer-Hansen, G., Sorensen, S., and Hansen, N.E. (2000). Subcellular distribution of urokinase and urokinase receptor in human neutrophils determined by immunoelectron microscopy. Ultrastruct. Pathol. 24, 175-182.
168. Petersen, L.C., Lund, L.R., Nielsen, L.S., Danø, K., and Skriver, L. (1988). One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem. 263, 11189-11195.
169. Petersen, L.C. (1997). Kinetics of reciprocal pro-urokinase/plasminogen activation-stimulation by a template formed by the urokinase receptor bound to poly(D-lysine). Eur. J. Biochem. 245, 316-323.
170. Pickford, A.R., Potts, J.R., Bright, J.R., Phan, I., and Campbell, I.D. (1997). Solution structure of a type 2 module from fibronectin: Implications for the structure and function of the gelatin-binding domain. Structure 5, 359-370.
171. Pierleoni, C., Castellucci, M., Kaufmann, P., Lund, L.R., and Schnack, N.B. (2003). Urokinase receptor is up-regulated in endothelial cells and macrophages associated with fibrinoid deposits in the human placenta. Placenta 24, 677-685.
172. Plesner, T., Ploug, M., Ellis, V., Rønne, E., Hoyer-Hansen, G., Wittrup, M., Pedersen, T.L., Tscherning, T., Danø, K., and Hansen, N.E. (1994a). The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 83, 808-815.
173. Plesner, T., Ralfkiær, E., Wittrup, M., Johnsen, H., Pyke, C., Pedersen, T.L., Hansen, N.E., and Danø, K. (1994b). Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am. J. Clin. Pathol. 102, 835-841.
174. Ploug, M., Rønne, E., Behrendt, N., Jensen, A.L., Blasi, F., and Danø, K. (1991). Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem. 266, 1926-1933.
175. Ploug, M., Plesner, T., Rønne, E., Ellis, V., Høyer-Hansen, G., Hansen, N.E., and Danø, K. (1992a). The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 79, 1447-1455.
176. Ploug, M., Eriksen, J., Plesner, T., Hansen, N.E., and Danø, K. (1992b). A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur. J. Biochem. 208, 397-404.
177. 2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J. Biol. Chem. 268, 17539-17546.
178. Ploug, M. and Ellis, V. (1994). Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 349, 163-168.
179. Ploug, M., Ellis, V., and Danø, K. (1994). Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 33, 8991-8997.
180. Ploug, M., Rahbek-Nielsen, H., Ellis, V., Roepstorff, P., and Danø, K. (1995). Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry 34, 12524-12534.
181. Ploug, M. (1998). Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry 37, 16494-16505.
182. Ploug, M., Rahbek-Nielsen, H., Nielsen, P.F., Roepstorff, P., and Danø, K. (1998). Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells. J. Biol. Chem. 273, 13933-13943.
183. Ploug, M., Østergaard, S., Gårdsvoll, H., Kovalski, K., Holst-Hansen, C., Holm, A., Ossowski, L., and Danø, K. (2001). Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40, 12157-12168.
184. Ploug, M., Gårdsvoll, H., Jørgensen, T.J., Lønborg, H.L., and Danø, K. (2002). Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: A potential target for anti-invasive cancer therapy. Biochem. Soc. Trans. 30, 177-183.
185. Plow, E.F., Freaney, D.E., Plescia, J., and Miles, L.A. (1986). The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol. 103, 2411-2420.
186. Pluskota, E., Soloviev, D.A., and Plow, E.F. (2003). Convergence of the adhesive and fibrinolytic systems: Recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 101, 1582-1590.
187. Powell, E.M., Campbell, D.B., Stanwood, G.D., Davis, C., Noebels, J.L., and Levitt, P. (2003). Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J. Neurosci. 23, 622-631.
188. Preissner, K.T. and Seiffert, D. (1998). Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb. Res. 89, 1-21.
189. Puente, X.S., Sanchez, L.M., Overall, C.M., and Lopez-Otin, C. (2003). Human and mouse proteases: A comparative genomic approach. Nat. Rev. Genet. 4, 544-558.
190. Pyke, C., Kristensen, P., Ralfkiær, E., Grøndahl-Hansen, J., Eriksen, J., Blasi, F., and Danø, K. (1991). Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138, 1059-1067.
191. Pyke, C., Eriksen, J., Solberg, H., Nielsen, B.S., Kristensen, P., Lund, L.R., and Danø, K. (1993a). An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett. 326, 69-74.
192. Pyke, C., Graem, N., Ralfkiær, E., Rønne, E., Høyer-Hansen, G., Brünner, N., and Danø, K. (1993b). Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53, 1911-1915.
193. Pyke, C., Ralfkiær, E., Rønne, E., Høyer-Hansen, G., Kirkeby, L., and Danø, K. (1994). Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24, 131-138.
194. Pöllänen, J., Hedman, K., Nielsen, L.S., Danø, K., and Vaheri, A. (1988). Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J. Cell Biol. 106, 87-95.
195. Quigley, J.P. (1976). Association of a protease (plasminogen activator) with a specific membrane fraction isolated from transformed cells. J. Cell Biol. 71, 472-486.
196. Rabbani, S.A., Rajwans, N., Achbarou, A., Murthy, K.K., and Goltzman, D. (1994). Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. FEBS Left. 338, 69-74.
197. Rakic, J.M., Maillard, C., Jost, M., Bajou, K., Masson, V., Devy, L., Lambert, V., Foidart, J.M., and Noel, A. (2003). Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol. Life Sci. 60, 463-473.
198. Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, N., Blasi, F., and Fazioli, F. (11996). Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15, 1572-1582.
199. Resnati, M., Pallavicini, I., Wang, J.M., Oppenheim, J., Serhan, C.N., Romano, M., and Blasi, F. (2002). The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 99, 1359-1364.
200. Reuning, U., Sperl, S., Kopitz, C., Kessler, H., Krüger, A., Schmitt, M., and Magdolen, V. (2003a). Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Des. 9, 1529-1543.
201. Reuning, U., Magdolen, V., Hapke, S., and Schmitt, M. (2003b). Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol. Chem. 384, 1119-1131.
202. Rifkin, D.B., Mazzieri, R., Munger, J.S., Noguera, I., and Sung, J. (1999). Proteolytic control of growth factor availability. APMIS 107, 80-85.
203. Rijneveld, A.W., Levi, M., Florquin, S., Speelman, P., Carmeliet, P., and van Der, P.T. (2002). Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol. 168, 3507-3511.
204. Rivera-Calzada, A., Robertson, D., MacFadyen, J.R., Boskovic, J., Isacke, C.M., and Llorca, O. (2003). Three-dimensional interplay among the ligand-binding domains of the urokinase-plasminogen-activator-receptor-associated protein, Endo180. EMBO Rep. 4, 807-812.
205. Roldan, A.L., Cubellis, M.V., Masucci, M.T., Behrendt, N., Lund, L.R., Danø, K., Appella, E., and Blasi, F. (1990). Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 9, 467-474.
206. Roshy, S., Sloane, B.F., and Moin, K. (2003). Pericellular cathepsin B and malignant progression. Cancer Metast. Rev. 22, 271-286.
207. Rømer, J., Lund, L.R., Eriksen, J., Pyke, C., Kristensen, P., and Danø, K. (1994). The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J. Invest. Dermatol. 102, 519-522.
208. Rømer, J., Bugge, T.H., Pyke, C., Lund, L.R., Flick, M.J., Degen, J.L., and Danø, K. (1996). Impaired wound healing in mice with a disrupted plasminogen gene. Nat. Med. 2, 287-292.
209. Rømer, J., Pyke, C., Lund, L.R., Ralfkiær, E., and Danø, K. (2001). Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. J. Invest. Dermatol. 116, 353-358.
210. Rønne, E., Behrendt, N., Ellis, V., Ploug, M., Danø, K., and Hoyer-Hansen, G. (1991). Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett. 288, 233-236.
211. Rønne, E., Pappot, H., Grøndahl-Hansen, J., Høyer-Hansen, G., Plesner, T., Hansen, N.E., and Danø, K. (1995). The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 89, 576-581.
212. Sameni, M., Dosescu, J., and Sloane, B.F. (2001). Imaging proteolysis by living human glioma cells. Biol. Chem. 382, 785-788.
213. Schnack Nielsen, B., Rank, F., Engelholm, L.H., Holm, A., Danø, K., and Behrendt, N. (2002). Urokinase receptor-associated protein (UPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. Int. J. Cancer 98, 656-664.
214. Schnitzer, J.E., McIntosh, D.P., Dvorak, A.M., Liu, J., and Oh, P. (1995). Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 269, 1435-1439.
215. Schuster, V. and Seregard, S. (2003). Ligneous conjunctivitis. Surv. Ophthalmol. 48, 369-388.
216. Segal, G., Lee, W., Arora, P.D., McKee, M., Downey, G., and McCulloch, C.A. (2001). Involvement of actin filaments and integrins in the binding step in collagen phagocytosis by human fibroblasts. J. Cell Sci. 114, 119-129.
217. Selvarajan, S., Lund, L.R., Takeuchi, T., Craik, C.S., and Werb, Z. (2001). A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat. Cell Biol. 3, 267-275.
218. Sheikh, H., Yarwood, H., Ashworth, A., and Isacke, C.M. (2000). Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor. J. Cell Sci. 113, 1021-1032.
219. Shliom, O., Huang, M., Sachais, B., Kuo, A., Weisel, J.W., Nagaswami, C., Nassar, T., Bdeir, K., Hiss, E., Gawlak, S. et al. (2000). Novel interactions between urokinase and its receptor. J. Biol. Chem. 275, 24304-24312.
220. Sidenius, N., Sier, C.F., and Blasi, F. (2000). Shedding and cleavage of the urokinase receptor (uPAR): Identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 475, 52-56.
221. Sidenius, N., Andolfo, A., Fesce, R., and Blasi, F. (2002). Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 277, 27982-27990.
222. Simon, D.I., Wei, Y., Zhang, L., Rao, N.K., Xu, H., Chen, Z., Liu, Q., Rosenberg, S., and Chapman, H.A. (2000). Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J. Biol. Chem. 275, 10228-10234.
223. Simons, K. and Toomre, D. (2000). Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 31-39.
224. Sitrin, R.G., Todd, R.F., III, Mizukami, I.F., Gross, T.J., Shollenberger, S.B., and Gyetko, M.R. (1994). Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 84, 1268-1275.
225. Sitrin, R.G., Todd, R.F., III, Albrecht, E., and Gyetko, M.R. (1996). The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J. Clin. Invest 97, 1942-1951.
226. Sitrin, R.G., Pan, P.M., Blackwood, R.A., Huang, J., and Petty, H.R. (2001). Cutting edge: Evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils. J. Immunol. 166, 4822-4825.
227. Solberg, H., Rømer, J., Brünner, N., Holm, A., Sidenius, N., Danø, K., and Høyer-Hansen, G. (1994). A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer 58, 877-881.
228. Solberg, H., Ploug, M., Høyer-Hansen, G., Nielsen, B.S., and Lund, L.R. (2001). The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J. Histochem. Cytochem. 49, 237-246.
229. Solberg, H., Rinkenberger, J., Danø, K., Werb, Z., and Lund, L.R. (2003). A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 130, 4439-4450.
230. Solomon, J.A., Chou, I.N., Schroder, E.W., and Black, P.H. (1980). Evidence for membrane association of plasminogen activator activity in mouse macrophages. Biochem. Biophys. Res. Commun. 94, 480-486.
231. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K.E., Montgomery, E., Lal, A., Riggins, G.J., Lengauer, C., Vogelstein, B., and Kinzler, K.W. (2000). Genes expressed in human tumor endothelium. Science 289, 1197-1202.
232. Stack, M.S. and Johnson, D.A. (1994). Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J. Biol. Chem. 269, 9416-9419.
233. Stahl, A. and Mueller, B.M. (1995). The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J. Cell Biol. 129, 335-344.
234. Stefanova, I., Horejsi, V., Ansotegui, I.J., Knapp, W., and Stockinger, H. (1991). GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 254, 1016-1019.
235. Stefansson, S., Kounnas, M.Z., Henkin, J., Mallampalli, R.K., Chappell, D.A., Strickland, D.K., and Argraves, W.S. (1995). gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. J. Cell Sci. 108, 2361-2368.
236. Stephens, R.W., Pöllänen, J., Tapiovaara, H., Leung, K.C., Sim, P.S., Salonen, E.M., Rønne, E., Behrendt, N., Danø, K., and Vaheri, A. (1989). Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J. Cell Biol. 108, 1987-1995.
237. Stephens, R.W., Nielsen, H.J., Christensen, I.J., Thorlacius-Ussing, O., Sørensen, S., Danø, K., and Brü nner, N. (1999). Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J. Natl. Cancer Inst. 91, 869-874.
238. Sternlicht, M.D. and Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516.
239. Stoppelli, M.P., Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Assoian, R.K. (1985). Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA 82, 4939-4943.
240. Sturge, J., Wienke, D., East, L., Jones, G.E., and Isacke, C.M. (2003). GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis. J. Cell Biol. 162, 789-794.
241. Sugita, Y., Nakano, Y., Oda, E., Noda, K., Tobe, T., Miura, N.H., and Tomita, M. (1993). Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59), a glycosylphosphatidylinositol-anchored membrane protein. J. Biochem. (Tokyo) 114, 473-477.
242. Tang, H., Kerins, D.M., Hao, Q., Inagami, T., and Vaughan, D.E. (1998). The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273, 18268-18272.
243. Tressler, R.J., Pitot, P.A., Stratton, J.R., Forrest, L.D., Zhuo, S., Drummond, R.J., Fong, S., Doyle, M.V., Doyle, L.V., Min, H.Y., and Rosenberg, S. (1999). Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth. APMIS 107, 168-173.
244. Vagnarelli, P., Raimondi, E., Mazzieri, R., De Carli, L., and Mignatti, P. (1992). Assignment of the human urokinase receptor gene (PLAUR) to 19q13. Cytogenet. Cell Genet. 60, 197-199.
245. r 55 000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100, 86-92.
246. Vu, T.H. and Werb, Z. (2000). Matrix metalloprotelnases: effectors of development and normal physiology. Genes Dev. 14, 2123-2133.
247. Wang, J., Mazar, A., Quan, N., Schneider, A., and Henkin, J. (1997). Plasminogen activation by pro-urokinase in complex with its receptor-dependence on a tripeptide (Spectrozyme plasmin). Eur. J. Biochem. 247, 256-261.
248. Webb, D.J., Nguyen, D.H., Sankovic, M., and Gonias, S.L. (1999). The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J. Biol. Chem. 274, 7412-7420.
249. Wei, Y., Waltz, D.A., Rao, N., Drummond, R.J., Rosenberg, S., and Chapman, H.A. (1994). Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269, 32380-32388.
250. Wei, Y., Lukashev, M., Simon, D.I., Bodary, S.C., Rosenberg, S., Doyle, M.V., and Chapman, H.A. (1996). Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
251. Wei, Y., Eble, J.A., Wang, Z., Kreidberg, J.A., and Chapman, H.A. (2001). Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol. Biol. Cell 12, 2975-2986.
252. Weis, W.I., Kahn, R., Fourme, R., Drickamer, K., and Hendrickson, W.A. (1991). Structure of the calcium-dependent lectin domain from a rat mannose-binding protein determined by MAD phasing. Science 254, 1608-1615.
253. Weis, W.I., Drickamer, K., and Hendrickson, W.A. (1992). Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 360, 127-134.
254. Werb, Z. (1997). ECM and cell surface proteolysis: Regulating cellular ecology. Cell 91, 439-442.
255. Werb, Z., Vu, T.H., Rinkenberger, J.L., and Coussens, L.M. (1999). Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107, 11-18.
256. Wienke, D., MacFadyen, J.R., and Isacke, C.M. (2003). Identification and characterization of the endocytic transmembrane glycoprotein endo180 as a novel collagen receptor. Mol. Biol. Cell 14, 3592-3604.
257. Wolf, B.B., Vasudevan, J., Henkin, J., and Gonias, S.L. (1993). Nerve growth factor-γ activates soluble and receptor-bound single chain urokinase-type plasminogen activator. J. Biol. Chem. 268, 16327-16331.
258. Wu, K., Yuan, J., and Lasky, L.A. (1996). Characterization of a novel member of the macrophage mannose receptor type C lectin family. J. Biol. Chem. 271, 21323-21330.
259. Xue, W., Kindzelskii, A.L., Todd, R.F., III, and Petty, H.R. (1994). Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J. Immunol. 152, 4630-4640.
260. Xue, W., Mizukami, I., Todd, R.F., III, and Petty, H.R. (1997). Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res. 57, 1682-1689.
261. Yamamoto, K. and Yamamoto, M. (1994). Cell adhesion receptors for native and denatured type I collagen and fibronectin in rabbit arterial smooth muscle cells in culture. Exp. Cell Res. 214, 258-263.
262. Ye, S. and Goldsmith, E.J. (2001). Serpins and other covalent protease inhibitors. Curr. Opin. Struct. Biol. 11, 740-745.
263. Zhou, H.M., Nichols, A., Meda, P., and Vassalli, J.D. (2000). Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J. 19, 4817-4826.
264. Zugmaier, G., Favoni, R., Jaeger, R., Rosen, N., and Knabbe, C. (1999). Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors. Ann. NY Acad. Sci. 886, 243-248.